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A B S T R A C T
Purpose
To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in
first-line ovarian cancer therapy.
Patients and Methods
Women with previously untreated advanced disease after surgery were randomly allocated to six
cycles of platinum-taxane chemotherapy plus placebo cycles (C)2 to C22 (R1); chemotherapy plus
bevacizumab C2 to C6 plus placebo C7 to C22 (R2); or chemotherapy plus bevacizumab C2 to C22
(R3). Patients were evaluated for history or on-study development of potential risk factors for GI
AEs defined as grade  2 perforation, fistula, necrosis, or hemorrhage.
Results
Of 1,873 patients enrolled, 1,759 (94%) were evaluable, and 2.8% (50 of 1,759) experienced a GI
AE: 10 of 587 (1.7%, R1), 20 of 587 (3.4%, R2), and 20 of 585 (3.4%, R3). Univariable analyses
indicated that previous treatment of inflammatory bowel disease (IBD; P  .005) and small bowel
resection (SBR; P  .032) or large bowel resection (LBR; P  .012) at primary surgery were
significantly associated with a GI AE. The multivariable estimated relative odds of a GI AE were
13.4 (95% CI, 3.44 to 52.3; P  .001) for IBD; 2.05 (95% CI, 1.09 to 3.88; P  .026) for LBR; 1.95
(95% CI, 0.894 to 4.25; P  .093) for SBR; and 2.15 for bevacizumab exposure (aggregated 95%
CI, 1.05 to 4.40; P  .036).
Conclusion
History of treatment for IBD, and bowel resection at primary surgery, increase the odds of GI AEs
in patients receiving first-line platinum-taxane chemotherapy for advanced ovarian cancer. After
accounting for these risk factors, concurrent bevacizumab doubles the odds of a GI AE, but is not
appreciably increased by continuation beyond chemotherapy.
J Clin Oncol 32:1210-1217. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Angiogenesis is a process integral to disease pro-
gression for solid tumors including ovarian cancer
andislargelypromotedbyvascularendothelialgrowth
factor (VEGF).1-17 Bevacizumab, a VEGFneutral-
izing monoclonal antibody,18 has demonstrated
single agent activity in phase II ovarian cancer tri-
als.19,20 Results of four phase III trials have been
reported, all demonstrating significant prolonga-
tion of progression-free survival when bevaci-
zumabwas combinedwith and continued beyond
standard chemotherapy.21-24
The incorporation of bevacizumab into first-
line ovarian cancer therapy has been controversial
because of lack of an overall survival benefit as yet
demonstrated for the entire studypopulations in the
two first-line phase III trials22,23 and to concerns
related to additional toxicity.25 GI wall disruption is
perhaps the most concerning adverse effect associ-
ated with bevacizumab and has been reported in
approximately 2.4% in general.25 In the phase III
first-line ovarian cancer trials, the aggregate ratewas
2.9% for 1,960 women allocated to receive bevaci-
zumab and 1.7% for 1,354 in the control groups.
Thepathogenesis for this complication in the setting
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ofbevacizumab therapy remainsunclear, and specific risk factorshave
been suggested only through historical studies. Therefore, the Gyne-
cologic Oncology Group (GOG) conducted a preplanned study em-
bedded within its first-line phase III trial.
PATIENTS AND METHODS
As shown in Figure 1, GOG 021822 was a double-blind, placebo controlled
first-line phase III clinical trial in which women with advanced cancers were
randomly allocated to one of three postoperative regimens: six cycles of intra-
venous carboplatin-paclitaxel chemotherapy cycles (C) 2 to C22 (R1); chem-
otherapyplusbevacizumab(15mg/kg)C2 toC6(R2); andchemotherapyplus
bevacizumab C2 to C22 (R3). Participation required stage III incompletely
resectable intra-abdominaldiseaseor stage IVdiseaseandaGOGperformance
status (PS) of 0 to 2. Because of concerns regarding the risk of GI perforation,
patientswith evidence of intestinal obstruction requiringparenteral hydration
or nutrition were excluded. Safety was monitored through physical and labo-
ratoryassessmentafter each treatmentcyclebyusingNationalCancer Institute
Common Toxicity Criteria version 3.
The presence or absence of potential baseline risk factors for the devel-
opment of GI adverse events (AEs) including surgical, vascular, hematologic,
and inflammatory conditions was collected on a medical history (MEDH)
form(onlineonly).Otherputative risk factorsderived fromthedatabase at the
completion of the trial included age at enrollment; GOGPS; the combination
of stage and debulking level; time from surgery to C1 treatment; time from
surgery to C2 treatment; and on-study development of intestinal obstruction,
complicated (febrile or grade 4) neutropenia, or thromboembolic events.
GI AEs were defined as grade 2 perforation, fistula, necrosis, or hem-
orrhage occurring as of C2 (when bevacizumab or placebo was initiated)
and 30 days of last protocol treatment.
The primary analysis of the clinical trial was based on progression-free
survival andwas conducted after 423 disease progression events or deaths had
been reported. The current study is based on data collected up to the time of
the primary data freeze, including only those with collected MEDH forms.
Univariable analyses to test the associationofGIAEswithpotential risk factors
were performed by using Fisher’s exact test for discrete variables and a logistic
model for continuous variables.26 A logistic model was used to estimate the
relative odds of a GI AE event because of bevacizumab, adjusted for other risk
factors.27 A time-dependent proportional hazardsmodel was used to evaluate
thenull hypothesis that theonsetof febrileneutropenia, intestinal obstruction,
or thromboembolic events was not associated with subsequent onset of a GI
AE.28 All P values are two-sided.
RESULTS
Patient Characteristics
Baseline characteristics of the 1,873 patients enrolled onto GOG
0218were similarlydistributedacross treatmentgroups (Table1).The
median agewas 60 years, over 80%had serous adenocarcinomas, and
themajorityof cancersweregrade3.Fortypercenthadstage IIIdisease
with residual intra-abdominal tumor implants  1 cm in diameter
after primary cytoreductive surgery, and 26% had stage IV disease.
MEDHformswerecollectedon1,759(94%)of the1,873patients
enrolled. As shown in Table 2, the frequency of putative medical risk
factors for GI AEs was similarly distributed across the three treatment
groups.Ofnote, at least 30%ofpatientshadavascular risk factor,with
582 (33%) under current medical management for hypertension and
226 (12.8%) having smokedwithin the previous year.With respect to
GI conditions, 147 patients (8.3%) underwent small bowel resection
Registered onto the trial
(N = 1,873)
Randomly assigned treatment assignment
R1: Carboplatin AUC 6
  Paclitaxel 175 mg/m2
  Placebo (starting on cycle 2)
  Every 3 weeks × 6
Maintenance phase:
  Placebo every 3 weeks for cycles 7–22
Included in efficacy analysis (n = 625)
  Disease progression or death (n = 423)
)651 = n( deiD  
)526 = n( 1R ot detacollA
  Received no study treatment (n = 4)
  Included in safety analysis (n = 621)
R3: Carboplatin AUC 6
  Paclitaxel 175 mg/m2
  Bevacizumab 15 mg/kg (starting on cycle 2)
  Every 3 weeks × 6
Maintenance phase:
  Bevacizumab 15 mg/kg every 3 weeks for 
    cycles 7–22
Included in efficacy analysis (n = 623)
  Disease progression or death (n = 360)
)831 = n( deiD  
)326 = n( 3R ot detacollA
  Received no study treatment (n = 5)
  Included in safety analysis (n = 618)
R2: Carboplatin AUC 6
  Paclitaxel 175 mg/m2
  Bevacizumab 15 mg/kg (starting on cycle 2)
  Every 3 weeks × 6
Maintenance phase:
  placebo every 3 weeks for cycles 7–22
Included in efficacy analysis (n = 625)
  Disease progression or death (n = 418)
)051 = n( deiD  
)526 = n( 2R ot detacollA
  Received no study treatment (n = 1)
  Included in safety analysis (n = 624)
)92 = n( elbigilenI
  Improper FIGO stage (n = 13)
  Inadequate specimen for central review (n = 5)
  Tumor of low malignant potential only (n = 3)
  Inappropriate histology (n = 7)
  Invalid primary tumor site (n = 1)
Fig 1. CONSORT diagram. AUC, area under the curve; FIGO, International Federation of Gynecology and Obstetrics staging system.
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(SBR), and 306 (17.4%) underwent large bowel resection (LBR) at
primary surgery for ovarian cancer. Relatively few had pre-existing
Crohn disease or ulcerative colitis.
The rates of potential risk factorsdeveloping after enrollmentbut
during treatment were low, including 39 patients (2.2%) with GI
obstruction, 86 (4.9%) with complicated neutropenia (either febrile
or grade 4), and 100 (5.7%) with either arterial or venous thrombo-
embolic events.
Incidence and Spectrum of GI AEs
Fifty-seven patients (3.2%) experienced a GI AE overall, and in
50patients (2.8%), the eventoccurredduringorbeyond treatmentC2
(start of bevacizumab or placebo). Three patients (one patient with
grade 3 hemorrhage, one with grade 3 fistula, and one with grade 5
bowel necrosis) are excluded from this report because for these cases a
MEDH case report formwas not submitted. As shown in Table 3, the
most common type of GI AE was perforation in 20 patients (40%),
followed by hemorrhage in 14 (28%) and fistula in 12 (24%). GI AEs
were reported in 10of 587patients (1.7%), 20of 587 (3.4%), and20of
585 (3.4%) for patients assigned to R1, R2, and R3, respectively.
Although therewere no grade 4 or 5 events in theR1 treatment group,
events classified as life-threatening or fatal occurred in six (1%) in the
R2 group and four (0.7%) in the R3 group. Figure 2 illustrates the
Table 1. Baseline Characteristics of the Source Population
Characteristic
R1
(n  625)
R2
(n  625)
R3
(n  623)
No. % No. % No. %
Age
Median 60 60 60
Range 25-86 24-88 22-89
Race
Non-Hispanic white 526 84 519 83 521 84
Asian 41 7 37 6 39 6
Non-Hispanic black 25 4 28 5 27 4
Hispanic 21 3 28 5 25 4
Other, specified 8 1 5  1 4  1
GOG PS
0 311 50 315 50 305 49
1 272 44 270 43 267 43
2 42 7 40 6 51 8
Stage surgical tumor debulking level†
III (macro)  1 cm‡ 218 35 205 33 216 35
III  1 cm§ 254 41 256 41 242 39
IV 153 25 164 26 165 27
Histology
Serous 541 87 519 83 524 84
Endometrioid 21 3 14 2 24 4
Clear cell 12 2 23 4 20 3
Mucinous 6 1 5  1 8 1
Other/not specified 45 7 64 10 47 7
Tumor grade
3 445 71 465 74 460 74
2 102 16 86 14 97 16
1 36 6 28 4 18 3
Not specified 42 7 46 7 48 8
NOTE. All clear cell tumors classified grade 3.
Abbreviations: GOG, Gynecologic Oncology Group; PS, performance status;
R1, chemotherapy plus placebo followed by placebo; R2, chemotherapy 
bevacizumab followed by placebo; R3, chemotherapy  bevacizumab fol-
lowed by bevacizumab.
Percentages may not total 100% because of rounding or categorization.
†International Federation of Gynecology and Obstetrics.
‡Stage III with  1 cm maximal diameter for any residual abdominal tumor.
§Stage III with  1 cm maximal diameter disease in any residual
abdominal tumor.
Results from central GOG Pathology Committee review updated
September 2010.
Table 2. Distribution of Medical History Risk Factors by Randomized
Treatment Group
R1
(n  587)
R2
(n  587)
R3
(n  585)
Total
(N  1,759)
No. % No. % No. % No. %
Currently takes medication
for hypertension 191 32.5 201 34.2 190 32.5 582 33.0
Has in the past taken
medication for
hypertension 30 5.1 34 5.8 25 4.3 89 5.1
Ever had peripheral
vascular disease with
claudication 5 0.8 2 0.3 3 0.5 10 0.5
Ever had myocardial
infarct or
cerebrovascular
accident 11 1.9 16 2.7 15 2.6 42 2.3
Smoked within past year 81 13.8 77 13.1 68 11.6 226 12.8
Currently takes insulin for
diabetes 9 1.5 11 1.9 12 2.0 32 1.8
Currently takes oral
medication for
diabetes 31 5.3 42 7.2 42 7.2 115 6.5
Ever diagnosed with
autoimmune disease 16 2.7 15 2.6 15 2.6 46 2.6
Ever had a peptic ulcer 11 1.9 15 2.6 11 1.9 37 2.1
Ever had an intestinal
obstruction
radiographically 16 2.7 18 3.1 18 3.1 52 3.0
Ever diagnosed with
Crohn disease 2 0.3 1 0.2 1 0.2 4 0.2
Ever diagnosed with
ulcerative colitis 6 1.0 7 1.2 3 0.5 16 0.9
Ever had medication or
surgery for
inflammatory bowel
disease 7 1.2 3 0.5 3 0.5 13 0.7
Ever had medication,
hospitalization,
antibiotics, or dietary
modification for
diverticulitis 8 1.4 16 2.7 12 2.0 36 2.0
Ever had Clostridium
difficile colitis 11 1.9 8 1.3 11 1.9 30 1.7
Ever had small bowel
resection with
anastomosis 53 9.3 51 8.7 54 9.2 158 9.0
Had small bowel resection
at primary surgery 48 8.2 48 8.2 51 8.7 147 8.3
Ever had a large bowel
resection with
anastomosis 95 16.2 113 19.2 114 19.5 322 18.3
Had large bowel resection
at primary surgery 90 15.3 108 18.4 108 18.5 306 17.4
Uses corticosteroids for a
chronic condition 11 1.9 8 1.4 11 1.9 30 1.7
Uses NSAID chronically 38 6.5 34 5.8 38 6.5 110 6.3
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; R1, chemo-
therapy plus placebo followed by placebo; R2, chemotherapy  bevaci-
zumab followed by placebo; R3, chemotherapy  bevacizumab followed
by bevacizumab.
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timing of events as a function of treatment group and cycle. Forty-six
(92%) occurred during C2 through C6 (chemotherapy phase), with
38 (75%) reported by C4.
Association Between Risk Factors and GI AEs
Univariable analysis indicated no association of GI AEs with age
at enrollment (P .593), baseline PS (P .297), the combination of
stage and residual disease after debulking surgery (P  .378), time
from surgery to C1 treatment (P .625), or time from surgery to C2
treatment (P .997; data not shown). There was also no significant
association between a GI AE and on-study development of GI ob-
struction (P .625), thromboembolic events (P .202), or compli-
cated neutropenia (P  .094, online only). In the time-dependent
proportional hazards model, the odds of a GI AE was greater among
the 74 patients in the study population who experienced febrile neu-
tropeniabefore theonsetof theGIAE,withahazardratioof2.55(95%
confidence limits, 0.607 to 10.74), but this was not statistically signif-
icant (P .201).
As shown in Table 4, a significant association with a GI AE was
observed forhistoryof inflammatoryboweldisease (IBD;P .020)or
treatmentof IBD(P .005); SBRwith anastomosis (P .039)or SBR
at primary surgery (P .032); and LBR with anastomosis (P .016)
or LBR at primary surgery (P .012). Amultivariable logistic model
wasused to estimate theoddsof aGIAEassociatedwithbevacizumab,
adjusted for significantly associated risk factors: IBDtreatment, SBRat
primary surgery, and LBR at primary surgery. Relative toR1, the odds
of aGIAEwere 2.15 (95%CI, 0.981 to 4.71) for R2 and 2.15 (95%CI,
0.981 to 4.70) for R3. Because the odds of a GI AE in each of the
bevacizumab treatedgroups relative toplacebowere similar, these two
groups were combined into a single group to provide a more precise
estimate of the effect of bevacizumab relative to placebo. As shown in
Table 5, multivariable analysis estimated that bevacizumab indepen-
dently increases the incidence of a GI AE by 2.15 (95% CI, 1.049 to
4.40; exactP .032),which is similar to theunivariable estimate, 2.19.
Previous treatment of IBD and LBR at primary surgery were also
independently associated with increased odds, whereas the impact on
increased odds for SBR was similar in magnitude to LBR but was not
statistically significant (P .093).
Finally, a logisticmodel with a treatment-factor interaction term
demonstrated no clear evidence that bevacizumab increased the odds
(P .10) of aGIAEassociatedwith risk factors found tobe significant
in univariable analyses (data not shown).
DISCUSSION
To our knowledge, this is the first prospective study examining risk
factors for serious GI AEs in the context of treatment of solid tumors
with anti-VEGF agents.
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Fig 2. Number of treatment cycles be-
fore grade 2 or worse GI adverse event
(AE). There were seven GI AEs before
treatment cycle 2 that are not included in
this figure. R1, chemotherapy plus pla-
cebo followed by placebo; R2, chemother-
apy  bevacizumab followed by placebo;
R3, chemotherapy  bevacizumab fol-
lowed by bevacizumab.
Table 3. Number of Grade 2 or Worse GI Adverse Event at or Beyond Cycle 2
by Type, Grade, and Treatment Group
GI Adverse
Event Type
R1 R2 R3
Total2 3 4 5 2 3 4 5 2 3 4 5
Fistula 1 3 0 0 1 2 1 0 1 3 0 0 12
GI leak 0 0 0 0 0 0 0 0 0 1 2 0 3
Necrosis 0 1 0 0 0 0 0 0 0 0 0 0 1
Perforation 0 2 0 0 1 5 2 3 0 5 0 2 20
Bleeding 2 1 0 0 3 2 0 0 3 3 0 0 14
Total 3 7 0 0 5 9 3 3 4 12 2 2 50
Abbreviations: R1, chemotherapy plus placebo followed by placebo; R2,
chemotherapy  bevacizumab followed by placebo; R3, chemotherapy 
bevacizumab followed by bevacizumab.
Three patients who experienced a grade 2 or worse GI adverse event after
cycle 2 had no medical history form submitted and are therefore not included
in this table or the rest of this report.
GI Events in Bevacizumab Phase III Trial
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In the initial report for GOG 0218, GI events were classified as
grade 2 perforation, fistula, necrosis, or leak, and the rates of these
eventsduringor after treatment cycle 2were1.2%,2.8%, and2.6%for
those enrolled to R1, R2, and R3, respectively.22 Although one may
consider these rates to be relatively low, they should be considered
clinically meaningful, as events are often life threatening,29,30 fre-
quently require major surgical intervention, andmay have long-term
adverse consequences. Thus, it is important that independent and
interactive risk factors for these complications are identified, allowing
for refined risk assessment, creation of guidelines for patient counsel-
ing, development of preventive strategies, and generation of hypoth-
eses related to underlying pathogenic mechanisms.
In the current study, GI AEs also included grade 2 GI hemor-
rhage,becausemucosalulcerationmanifestedasbleedingwashypoth-
esized to be mechanistically related to perforation on the basis of
pathology studies.31 Using our modified definition for the current
study, the rate of GI AEs was 3.4% in each bevacizumab treatment
group, approximatelydouble that seen in the groupassigned to chem-
otherapy alone and, not unexpectedly, remained an independent risk
factor inmultivariable analysis.We examined only events after initia-
tion of bevacizumab or placebo to accurately factor in relative odds
attributable to bevacizumab.
Table 4. Univariable Analyses of Medical History Risk Factors and
Development of a GI Adverse Event
 GI AE
(n  1,709)
 GI AE
(n  50)
PNo. % No. %
Medication for hypertension .170
Never 1,063 98 25 2.3
Past 86 97 3 3.4
Current 560 96 22 3.8
Peripheral vascular disease
with claudication 1.00
Never 1,699 97 50 2.9
Ever 10 100 0.0 0.0
Myocardial infarct or
cerebrovascular
accident .114
Never 1,670 97 47 2.7
Ever 39 93 3 7.1
Smoked within past year .829
No 1,490 97 43 2.8
Yes 219 97 7 3.1
Current medication for
diabetes .909
No 1,566 97 46 2.9
Oral 112 97 3 2.6
Insulin 31 97 1 3.1
Diagnosis of autoimmune
disease .379
Never 1,665 97 48 2.8
Ever 44 96 2 4.4
Peptic ulcer .624
Never 1,672 97 50 2.9
Ever 37 100 0 0.0
Intestinal obstruction
radiographically .658
Never 1,659 97 48 2.8
Ever 50 96 2 3.9
Diagnosis of IBD .020
Never 1,692 97 47 2.7
Crohn disease 4 100 0 0.0
UC 13 81 3 18.75
Medication or surgery for
IBD .005
Never 1,699 97 47 2.7
Ever 10 77 3 23
Medication, hospitalization,
antibiotics, or dietary
modification for
diverticulitis 1.000
Never 1,674 97 49 2.8
Ever 35 97 1 2.8
Diagnosis of Clostridium
difficile colitis .209
Never 1,681 97 48 2.8
Ever 28 93 2 6.7
SBR with anastomosis .039
Never 1,560 97 41 2.6
Ever 149 94 9 5.7
SBR at primary surgery .032
No 1,571 97 41 2.5
Yes 138 94 9 6.1
LBR with anastomosis .016
Never 1,403 97 34 2.4
Ever 306 95 16 5.0
(continued in next column)
Table 4. Univariable Analyses of Medical History Risk Factors and
Development of a GI Adverse Event (continued)
 GI AE
(n  1,709)
 GI AE
(n  50)
PNo. % No. %
LBR at primary surgery .012
No 1,419 98 34 2.3
Yes 290 95 16 5.2
Current corticosteroids for a
chronic condition .582
Yes 1,680 97 49 2.8
No 29 97 1 3.3
Current chronic NSAID use .367
Yes 1,600 97 49 3.0
No 109 99 1 0.9
Abbreviations: AE, adverse event; IBD, inflammatory bowel disease; LBR,
large bowel resection; NSAID, nonsteroidal anti-inflammatory drug; SBR,
small bowel resection; UC, ulcerative colitis.
Table 5. Results of a Logistic Model Assessing the Association Between GI
Adverse Events and Risk Factors Significantly Associated With GI Adverse
Events in Univariable Analyses
Model Covariate
Relative Odds of Grade  2 GI
AE
P
Estimated
Odds 95% CI
IBD treatment 13.40 3.44 to 52.30  .001
LBR at primary surgery 2.05 1.09 to 3.88 .026
SBR at primary surgery 1.95 0.894 to 4.25 .093
BEV treatment 2.15 1.05 to 4.40 .032
Abbreviations: AE, adverse event; BEV, bevacizumab; IBD, inflammatory
bowel disease; LBR, large bowel resection; SBR, small bowel resection.
Burger et al
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The finding that bevacizumab exposure was associated with in-
creased odds of aGIAEwith an odds ratio of 2.15 in the current study
is supported by a meta-analysis by Hapani et al29 examining 12,294
patients with a variety of nongynecologic solid tumors from 17 ran-
domized controlled trials. This demonstrated the incidence of GI
perforation tobe0.9%amongpatients receivingbevacizumaband the
relative odds of GI perforation compared with control patients to be
2.14 (95% CI, 1.19 to 3.85; P  0.011). Interestingly, in the current
study, theodds ratio for the associationofbevacizumabexposurewith
aGIAEwas identical (2.15) forboth those receivingbevacizumabonly
during the chemotherapy phase and those receiving bevacizumab
during and continued beyond the chemotherapy phase, suggesting
that there is no significant additional risk of bevacizumab continued
beyond primary platinum-taxane chemotherapy.
The etiology of GI AEs as defined above has been found to be
multifactorial and include traumatic, vascular, infectious/inflamma-
tory, or toxic insults to the GI tract with impairment in healing as the
common denominator.29 This explains our selection of hypothetical
risk factors for investigation.Except forbevacizumabexposure, all risk
factors examined were similarly distributed across treatment groups
in the clinical trial.We found that theoddsof aGIAEwas significantly
associatedwith bevacizumab exposure; history of IBDor treatment of
IBD; and previous SBR/LBRwith anastomosis or SBR/LBR at time of
primary surgery before enrolling onto GOG 0218.
Although the mechanisms by which bevacizumab may contrib-
ute to development of bowel perforation remain elusive, the prepon-
derance of data suggests impairment of healing at sites of GI injury to
be the common denominator. Early preclinical studies before the
development of an anti-VEGF monoclonal antibody demonstrated
several naturally occurring and synthetic antiangiogenic agents to
impair healing after cutaneous surgical trauma32,33 and colonic anas-
tomoses,34,35whereas others demonstratednoclear impact onhealing
of cutaneouswounds despite reduction inmicro-vascularmaturation
and granulation tissue.36-39 Data pooled from two positive phase III
randomized trials of bevacizumab in first-line therapy of metastatic
colorectal cancer involving 1,132 patients demonstrated surgical
woundhealing complications in 1.3%of those receiving bevacizumab
versus 0.5% in control patients. Though inconclusive, bevacizumab
induced necrosis of tumor invading the bowel wall as an alternative
process is suggested by retrospective analyses of clinical,40,41 patho-
logic,30,42 and radiologic20 data. Indeed, the odds for GI perforation
appear to be greater for patientswith tumors involving the abdominal
cavity, such as colorectal,29 renal cell,29 and ovarian,43 which suggests
that this is a possible mechanism. However, one cannot exclude the
possibility that such tumors are more likely to be associated with
confounding factors, such as tumor infiltration of themesentery with
compromise blood supply, intestinal obstruction, and previous intes-
tinal surgery. In addition, this would not explain the association of
such events with bevacizumab in patients with cancer who have no
evidence of intra-abdominal tumor and no other obvious risks.29,44 A
limitation of the current study is our inability to examine GI wall
involvement by tumor prospectively because no reliable methods of
diagnosis or documentation have been established. Another possibil-
ity is that bevacizumab could limit the blood flow to the splanchnic
microvasculature via thrombosis or vasoconstriction,45,46 leading to
GI ischemia, but evidence for this hypothesis is limited.
Wealso found thathistoryof bowel resectionwas associatedwith
a two- to threefold increase in theoddsof aGIAE.Thevastmajorityof
GI AEs in this subset of patients is presumed to be due to anastomotic
dehiscence, awell-knowncomplicationof intestinal surgery ingeneral
andmost commonly associatedwith colorectal anastomoses.47-49 The
risk of anastomotic leak in patients with advanced ovarian carcinoma
and related gynecologic malignancies undergoing colorectal surgery
may be a particular problem because of protein malnutrition that is
commonwhen these surgeries are performedbefore induction chem-
otherapy.50 Results of a phase III trial reported by Vergote et al,51 in
whichwomenwith advanced ovarian cancer were randomly assigned
to undergo primary debulking surgery before six cycles of post-
operative chemotherapy or to undergo neoadjuvant chemotherapy
(NACT)with intervaldebulking surgeryafter the thirdcycleofNACT,
demonstrated that the rate of bowel resection at interval debulking
surgery after NACT was approximately 50% lower (8.7% of 322 pa-
tients) than the rate at primary debulking surgery (15.5% of 310
patients).51Thedirect impactonthisdifferenceonthedevelopmentof
a GI AE as herein defined is unknown.
An important observation made in the current study is that not
only were bevacizumab exposure and previous treatment of IBD and
LBR at primary surgery independently associated with an increase in
the odds of a GI AE, but also that in a logistic model there was no
evidence that bevacizumab exacerbated the risk of aGIAEwhen these
risk factors were present.
The interpretation of our data has additional limitations. First,
several variables hypothetically associated with GI AEs were not spe-
cifically analyzed, including GI obstruction before treatment (an ex-
clusion criterion for GOG 0218), protein malnutrition, specific
chemotherapeutic regimen (identical across treatment groups), or
bevacizumab dose density. Unfortunately we did not specifically ex-
amine laboratory indices of nutrition, such as pretreatment serum
albumin. However, we found no association with PS, which may
reflect nutritional state. Cytotoxic regimens including taxanes have
been implicated, with mechanisms including necrosis of invasive tu-
mor, bowel wall cytotoxicity, or transmigration of bacteria secondary
toneutropenia.52-55Theassociationofbevacizumabdosedensitywith
risk of GI AEs has been suggested in the meta-analysis by Hapani et
al29; however, these were univariable analyses unadjusted for other
factors suchas typeof combinedchemotherapeutic agents.GOG0218
utilized only one dose density for bevacizumab5 mg/kg per week.
The results of an open label phase III trial of bevacizumab in first-line
therapy consisting of the same chemotherapy regimen utilized in
GOG0218butwithabevacizumabdosedensityof 2.5mg/kgperweek
demonstrated a similar frequency of GI AEs.23 Thus far there is no
evidenceof a relationship tobevacizumabdosedensity in themanage-
ment of patients with ovarian cancer.
Second, type I and type II statistical error could have influenced
results and conclusions. Some positive findings could possibly be due
to unadjusted multiple hypothesis testing. IBDs are rare conditions
associated with development of GI perforation and fistula (particu-
larly for Crohn disease).56-58 In the current study, though a history of
IBD or treatment thereof was reported in 1% of the study popula-
tion, those with a history of treatment for IBD had a 13-fold higher
odds of a GI AE compared with those without such history.
Themore concerning issue relates to negative findings where no
statistically significant associations were found between biologically
plausible risk factors and GI AEs. There are several possible explana-
tions, including the relatively low number of events and the low
frequency of some risk factors, creating imprecision in risk estimates.
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Arguably, examples of this phenomenon may be on-study develop-
ment of GI obstruction or complicated neutropenia, occurring in 39
(2.2%) and 86 (4.9%), respectively. Intestinal obstruction is a well-
established risk factor for GI perforation59 and has retrospectively
been found to be a risk factor in a registry of approximately 2,000
patientswithmetastatic colorectal cancer treatedwithbevacizumab.41
Severe neutropenia is thought to permit trans-mural invasion of
pathogenicbacteria andhasbeen implicatedas a risk factor for entero-
colonic perforation.60
Third, our results may not be completely applicable to other
primary treatment scenarios, suchas forpatientswithnomacroscopic
residual disease after initial surgery, receiving alternative regimens
such as dose-dense paclitaxel with carboplatin,61 treated with com-
bined intraperitoneal-intravenous chemotherapy, or receiving induc-
tion NACT with interval surgical cytoreduction. Furthermore, the
results may be even less applicable to those receiving bevacizumab
with or without chemotherapy in the recurrent disease setting.
On the basis of our findings, we conclude that history of treat-
ment for IBD and colon resection during initial surgery for advanced
ovarian cancer appears to increase the risk of bowel perforation, fis-
tula, necrosis, or bleeding during first-line platinum-taxane based
treatment. After accounting for these risk factors, first-line treatment
with bevacizumab also increases the odds of such a GI event, but
bevacizumabdoesnot appear to synergizewith theseother risk factors
or increase theoddsofGIAEswhen it is continuedafter completionof
platinum-taxane primary chemotherapy. Patients preparing for first-
line therapy after surgery should be carefully counseled regarding the
potential impact of these interventions and conditions on their indi-
vidual risks.
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GLOSSARY TERMS
angiogenesis: the process involved in the generation of new
blood vessels. Although this is a normal process that naturally
occurs and is controlled by so-called on and off switches, block-
ing tumor angiogenesis (antiangiogenesis) disrupts the blood
supply to tumors, thereby preventing tumor growth.
bevacizumab: also called Avastin (Genentech, South San
Francisco, CA). Bevacizumab is a recombinant, humanized,
monoclonal antibody that binds and neutralizes the vascular
endothelial growth factor, thus acting as an antiangiogenic
agent.
proportional hazards: semiparametric approach to survival analysis
developedbyCox in 1972.Unlike product-limit (Kaplan-Meier) survival analy-
ses, which are restricted to categorical predictor variables anddonot produce a
risk estimate, proportional hazardsmodels can accommodate continuous and
ordinal variables aswell as allow for the inclusionofmultiple predictor variables
to compute adjusted risk estimates. Proportional hazardsmodels are based on
the fundamental premise that all individuals have the samebaseline hazard that
varies as a function of time [(t)], but that exposure to the independent variable
changes the hazard by a fixed value [h(x)].What is parameterized in themodel
is the value of this fixed effect per unit increase of the predictor variablewhereas
the value of (t) remains uncharacterized.
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